A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan - Haranaka, M; Young, Song J; Huang, K-C (Vaccine, 2024)